AKAlexander Vladimirovich Korotkikh

Alexander Vladimirovich Korotkikh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alexander Vladimirovich Korotkikh has a total of 349 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prevention of radial artery occlusion with Rivaroxaban after transradial coronary interventions: results of a single-center randomized clinical trial

    by A. V. Korotkikh, A. M. Babunashvili, А. В. Коротких, А. М. Бабунашвили

    The transradial approach is the gold standard for coronary interventions, however, radial artery occlusion (RAO) remains a frequent complication limiting the possibility of repeated use of the vessel. Despite all existing methods for RAO prevention, they are all aimed at influencing the radial artery (RA) during or immediately after the procedure. Aim: To evaluate the efficacy and safety of RAO prevention with Rivaroxaban 2.5 mg twice daily for 3 months in patients after coronary interventions performed via the transradial approach (TRA). Material and Methods. A single-center randomized controlled trial was conducted (n = 300). Patients were randomly assigned (1:1) to one of two groups: those receiving Rivaroxaban 2.5 mg twice daily for 3 months after transradial endovascular coronary intervention (Rivaroxaban group – Group I), and those receiving standard treatment (control group – Group II). The primary endpoint was the incidence of RAO at day 7 after puncture, as well as at 1 and 3 months; assessed by ultrasound Doppler control. Secondary endpoints were hemorrhagic complications according to the BARC classification. Results. The administration of Rivaroxaban led to a significant reduction in RAO incidence at all follow-up time points: day 7 – 0.7% vs. 12.7%, p < 0.001; OR = 0.046 (95% CI: 0.006–0.35); 1 month – 3.3% vs. 14.7%, p < 0.001; OR = 0.20 (95% CI: 0.07–0.54); 3 months – 4.0% vs. 13.3%, p = 0.004; OR = 0.27 (95% CI: 0.10–0.72). No cases of severe bleeding BARC type 3–5 were observed in either group. The number of minor bleeding events (BARC 1) in the entire sample was 1.3%, with no statistically significant difference between the groups: 1.0% vs. 0.33%, p = 0.624; OR = 3.04 (95% CI: 0.31–29.6). Conclusions. The administration of Rivaroxaban 2.5 mg twice daily for 3 months can be considered an effective and safe method for RAO prevention in patients after elective coronary interventions performed via the transradial approach.

  • Prevention of radial artery occlusion with rivaroxaban after interventional coronary interventions using transradial access: Results of a single-center randomized clinical trial

    by Alexander Korotkikh, Avtandil Babunashvili

    Background: Transradial access is the preferred approach for coronary angiography and percutaneous coronary intervention; however, radial artery occlusion (RAO) remains the most common vascular complication and may preclude repeat radial access, radiocephalic arteriovenous fistula creation, and use of the radial artery as a coronary bypass conduit. Most preventive strategies target procedural factors, whereas extended pharmacologic prophylaxis remains insufficiently studied. Objective: To evaluate the efficacy of rivaroxaban 2.5 mg twice daily for 3 months in preventing RAO after transradial coronary procedures and to assess bleeding events during follow-up. Methods: This prospective, single-center, open-label randomized controlled trial enrolled 300 patients with chronic coronary syndrome undergoing coronary angiography or percutaneous coronary intervention via conventional transradial access. Patients were randomized (1:1) to rivaroxaban 2.5 mg twice daily for 3 months or standard therapy without additional anticoagulation. Duplex ultrasound, performed by a blinded assessor at 7 days, 1 month, and 3 months, evaluated the primary endpoint of complete RAO. Bleeding was classified according to Bleeding Academic Research Consortium criteria. Adjusted associations were assessed using Firth penalized logistic regression. Results: Rivaroxaban significantly reduced RAO at 7 days (0.7% vs 12.7%; p < 0.001), 1 month (3.3% vs 14.7%; p < 0.001), and 3 months (4.0% vs 13.3%; p = 0.004). At 3 months, the absolute risk reduction was 9.3%, corresponding to a number needed to treat of approximately 11. After adjustment for chronic kidney disease, radial artery diameter, and procedure duration, rivaroxaban remained independently associated with lower RAO (adjusted OR 0.22, 95% CI 0.08–0.61; p = 0.003). No BARC type 3–5 bleeding occurred; four BARC type 1 events were observed. Conclusions: In this selected single-center population, prolonged low-dose rivaroxaban was associated with a substantial reduction in ultrasound-detected RAO after transradial coronary procedures. These findings support further multicenter placebo-controlled trials but do not justify routine prophylactic use pending additional safety, cost-effectiveness, and comparative-effectiveness data.


  • Open Access

    Distal radial access in coronary procedures: a systematic review and meta-analysis of randomized clinical trials over the past 20 years

    by A. V. Korotkikh, A. M. Babunashvili, А. В. Коротких, А. М. Бабунашвили

    Distal radial access (DRA) is promoted to reduce the incidence of radial artery occlusion (RAO) after interventional coronary procedures while preserving the be­nefits of the classic radial artery approach. Despite the rapid adoption of this technique, the clinical utility of DRA in various clinical scenarios (coronary angiography, elective percutaneous coronary intervention (PCI), acute coronary syndrome, and primary PCI for ST-segment elevation myocardial infarction) remained heterogeneous due to differences in surgeon experience, hemostasis protocols, and occlusion verification methods. Aim . To systematically search and critically analyze randomized clinical trials (RCTs) of DRA in interventional coronary interventions over the past 20 years, with a separate description of excluded non-randomized sources and se­condary reviews. Material and methods . A search was performed using the PRISMA 2020 criteria in PubMed, Web of Science, Google Scholar, and eLIBRARY. A supplementary search of reference lists and ClinicalTrials.gov was also conducted. The main synthesis included only RCTs in adult patients comparing DRA with traditional radial access for coronary angioplasty and/or PCI. Retrospective studies, case-control studies, case reports, and secondary reviews were excluded from the primary synthesis but were reflected in separate tables. Results . The qualitative synthesis included 15 RCTs, and the quantitative meta-ana­lysis included 12 RCTs with an extractable number of events for RAO. In the pooled analysis, DRA significantly reduced the risk of RAO compared with the traditional approach (RR 0,29; 95% CI 0,21-0,40; I2=4,1%) but was associated with a higher probability of access conversion/failure (RR 2,59; 95% CI 1,34-5,00). Conclusions . The most consistent advantage of DRA was observed in reducing hemostasis time and incidence of RAO, especially in studies with Doppler verification and standardized (patent) hemostasis. For primary PCI of STEMI, DRA appears feasible in experienced centers. However, it should not prolong the time to reperfusion and requires readiness for rapid conversion to the traditional radial or femoral approach.

  • Open Access

    Comparison of distal and transradial approaches for endovascular procedures on the forearm radial artery (a systematic review and meta-analysis)

    by A. V. Korotkikh, A. M. Babunashvili

    The distal radial access (DRA) in the anatomical snuffbox area is considered as a modification of the transradial access (TRA), potentially reducing the incidence of radial artery occlusion (RAO) and local complications, while preserving the proximal radial artery (RA) segment for future interventions. Aim : To evaluate the efficacy and safety of DRA compared with conventional TRA for endovascular procedures based on current randomized clinical trials (RCTs) and meta-analyses (2022–2026), with a focused quantitative synthesis of randomized evidence and a narrative overview of other procedural setting. Methods . PubMed/MEDLINE, Web of Science Core Collection, Google Scholar, and eLIBRARY (including manual search of reference lists) were searched using PRISMA 2020 from January 1, 2022, to February 1, 2026. Only meta-analyses and prospective RCTs were included; Retrospective studies, case-control designs, and clinical cases were excluded. The primary outcome was RAO (by assessment time), secondary outcomes were technical access success, access change (crossover), local complications, hemostasis time, operator radiation exposure, and ergonomics. A sensitivity analysis was performed at ≤ 48 hours (at discharge) and 30–90 days. Results . Nine RCTs (only coronary procedures) were included in the quantitative synthesis of RAO. In the subgroup of comparable timing (48 hours / 30 days / 60 days / 1 month / 3 months; k = 6), DRA reduced the risk of LA: RR = 0.37 (95% CI 0.25–0.54), I² = 0%. A risk reduction was also found for RAO at 24 hours ( k = 1). 12-month data are presented in the TENDERA RCT. Sensitivity analysis stratified by the time of RAO assessment showed consistent results. Conclusions . According to RCTs and meta-analyses, DRA is associated with a reduction in RAO and several local complication/ hemostasis benefits in 2022–2026. However, it often requires crossover and longer cannulation times during the development phase. The “protective effect” of DRA on the radial artery remains stable over different observation periods. Practical implications: DRA is appropriate for patients where preserving the proximal radial artery is important (repeated interventions, potential bypass/fistula), provided experience and patent hemostasis and/or ultrasound-guided protocols are available.

  • Open Access

    Trends in intravascular diagnostics development in the Russian Federation: four-year data from the Russian registry on intravascular imaging and physiology methods

    by V. V. Demin, A. M. Babunashvili, D. V. Duplyakov, T. V. Kislukhin, E. Yu. Kostyrin, O. E. Zauralov, A. V. Demin, A. V. Ter-Akopyan, S. A. Dolgov, Z. Kh. Shugushev, et al.

    Aim. To analyze the results of the use and development trends of intravascular diagnostic methods based on four-year data from the Russian registry on the use of intravascular imaging and physiology methods. Material and methods . In 2024, data on 13125 examinations in 5408 patients were entered into the registry, and the registry includes information on 33154 procedures in 14311 patients. The database design and content continued to be refined, with several sections significantly revised. The most significant changes affected the sections on immediate and late surgical outcomes. To standardize the intravascular imaging evaluation during endovascular interventions, quantitative parameters were introduced, with semi-automated calculation of final coefficients and derivation of final conclusions. Results. Over 4 years, 30 departments from 18 Russian cities participated in the registry. The average number of examinations per patient increased from 1,96 in 2021 to 2,43 in 2024. There is a trend toward an increasing role for intravascular ultrasound, with a decline in the use of optical coherence tomography and, to a lesser extent, fractional flow reserve. The share of intravascular ultrasound increased from 37% to 66%, while optical coherence tomography decreased from 23% to 5%, and fractional flow reserve decreased from 40% to 29%. Approximately 20% of studies were performed for acute coronary syndrome (19% of which were for ST-segment elevation myocardial infarction), while 2% were performed for noncoronary pathology. The largest number of studies were performed at the initial and final stages of surgery, followed by primary diagnostic studies, intraoperative monitoring, and diagnostic studies during patient follow-up. Conclusion . The registry provides an objective means of analyzing intravascular diagnostic methods in Russia. Improving the registry and standardizing approaches to performing and evaluating data from intravascular techniques allows for an objective assessment of intervention results and contributes to their improvement. A number of clinics across the country routinely use intravascular diagnostic techniques, including for acute coronary syndrome and non-coronary pathology.

  • Assessment of results of using three types of vascular access for isolated hepatic chemoperfusion

    by Vladimir M. Unguryan, Anton N. Kazantsev, Aleksandr V. Korotkikh, Sergey A. Ivanov, Yuriy V. Belov, Andrey D. Kaprin

    INTRODUCTION: Uveal melanoma (UM) is an oncological disease, which develops metastases mainly to the liver. One of treatments for this pathology is isolated hepatic chemoperfusion (IHCP). The implementation of this method requires surgical isolation of the liver from the systemic circulation and the use of a heart-lung machine. Due to a small number of observations of this treatment method in the world, the optimal vascular access for its implementation has not been determined so far. AIM: To analyze the in-hospital results of IHCP in patients with UM metastases performed from three different vascular accesses. MATERIALS AND METHODS: Over three years, 38 IHCP procedures were performed of the Kostroma Clinical Oncological Dispensary. Depending on the vessels into which the cannula for perfusion with Melphalan was inserted, patients were divided into 3 groups: group 1 with cava-porto-arterial access (perfusion into the inferior vena cava, portal vein, and common hepatic artery), n = 14; group 2 with cava-arterial access (perfusion into the inferior vena cava and common hepatic artery), n = 21; group 3 with a forced access, n = 3. The study took into account major complications: death, bleeding; and minor complications: tumor lysis syndrome, abscess of the left lobe of the liver, peritonitis, a systole, deep vein thrombosis of the lower limbs, hydrothorax, acute liver failure, anasarca, polyserositis, ischemic cholangiopathy, thrombosis of the common hepatic artery, detachment of the common hepatic artery intima. A combined endpoint was the achievement of at least one of the listed complications. In case of several complications in one patient, they were not summed up and were considered as ‘1’. RESULTS: In the postoperative period, the highest number of bleedings including those requiring revision, was noted in groups 1 and 3. The combined endpoint in the total sample made 42.11% and was lowest in group 2. Fatal outcomes were recorded in 3 cases (2 in group 1 and 1 in group 2), and were caused by increasing liver failure. CONCLUSION: The lowest number of complications IHCP was identified with cava-arterial access. Further continuation of the study is necessary to investigate the immediate and remote outcomes of IHCP.


  • Open Access

    Traditional Versus Distal Radial Access for Coronary Diagnostic and Revascularization Procedures: Final Results of the TENDERA Multicenter, Randomized Controlled Study

    by Avtandil M. Babunashvili, Samir Pancholy, Aleksei B. Zulkarnaev, Alexander L. Kaledin, Igor N. Kochanov, Alexander V. Korotkih, Dmitriy S. Kartashov, Mikhail A. Babunashvili

    Background: Traditional transradial access (TRA) is widely used for coronary and non‐coronary interventions with significant improvements in procedural outcomes; however, it is associated with RAO that precludes repeat use of the same artery for possible future TRI and other purposes. Distal radial access (DRA) has been proposed as an effective alternative to decrease RAO rates. Published literature describing the RAO rate after DRA versus TRA from various RCT and clinical registries has shown conflicting results.Objectives: This study compared the forearm radial artery occlusion (RAO) rate assessed by Doppler ultrasound between distal and conventional radial access at 1‐year follow‐up after the initial procedure.Methods: TENDERA was a multicenter, randomized controlled study comparing DRA versus TRA for coronary diagnostic and interventional procedures using 5 or 6F hydrophilic‐coated sheaths. The primary endpoint was forearm RAO at 12 months after radial access. The secondary endpoints included puncture time, sheath insertion and total procedure time, radiation dose, and vascular access site‐related complications.Results: Eight hundred and fifty patients were randomized to either TRA (n = 418) and DRA (n = 432) groups. In the intention‐to‐treat analysis, the rate of forearm RAO at 12 months was observed in 39 patients (4.6%) and was significantly reduced in the DRA group compared with the TRA group (2.5% vs. 6.7%, RR 2.59 [95% CI 1.29–5.59], p = 0.010). Analysis in per protocol population has shown consistent results with forearm RAO rate 2.8% in the DRA group versus 6.5% in the TRA group (p = 0.008). The crossover rate was higher (4.6% vs. 1%, p = 0.013) and median hemostasis time was shorter (156.5 min vs. 180 min, p < 0.001) with DRA. Overall bleeding (BARC 1–2) and postprocedure hematoma > 5 cm occurred less frequently in the DRA group compared with the TRA group (3.2% vs. 20.5%, p < 0.001% and 9.0% vs. 27.0%, p < 0.001, respectively). No significant differences were observed in total procedure time and radiation dose between groups.Conclusions: DRA for coronary diagnostic and interventional procedures is associated with reduced forearm RAO rate and shorter hemostasis time, but a longer sheath insertion time and higher crossover rate compared with TRA.Trial Registration: ClinicalTrials.gov: NCT04211584.


  • Open Access

    Prognostic value of no-reflow phenomenon in myocardial infarction: the role of the severity of ischemic damage

    by A. A. Frolov, M. G. Kashtanov, A. V. Korotkikh, I. G. Pochinka, I. A. Frolov, K. V. Kuzmichev, A. S. Mukhin, E. G. Sharabrin

    Aim. To create a scale for assessing the myocardial ischemia severity and to study the effect of concomitant ischemia on the prognosis of myocardial infarction (MI) complicated by no-reflow phenomenon during percutaneous coronary intervention (PCI).Material and methods. A single-center cohort study was conducted. There were following inclusion criteria: MI, PCI, total ischemic time Results. A total of 18079 patients with acute coronary syndrome were analyzed, while 219 were included. After comparison, 105 patients remained as follows: group 1 — 75 patients without assessed severe ischemia; group 2 — 30 patients with assessed severe ischemia. During the hospital stage, 6 (8,0%) and 9 (30,0%) patients died, respectively, pConclusion. Concomitant severe ischemic damage in MI complicated by no-reflow during PCI is associated with worse left ventricular function and a higher death risk at the hospital stage and in the long-term follow-up period.


  • Open Access

    Distal radial access as an alternative to conventional radial access in coronary angiography and percutaneous coronary interventions

    by A. V. Korotkikh, A. M. Babunashvili, A. L. Kaledin, R. V. Akhramovich, V. V. Derkach, R. M. Portnov, D. S. Kartashov

    Aim. To evaluate immediate and medium-term (3 months) results of safety and effectiveness of distal versus proximal radial access for coronary interventions.Material and methods. An analysis of 776 patients of the prospective randomized TENDERA trial was performed: distal radial access (DRA) group — 1391 patients; proximal radial access (PRA) group — 385 patients. After excluding patients with failed primary access, the primary sample sizes decreased (DRA — 371, PRA — 382). Access-site crossover rate was statistically higher in the DRA group (5,1% and 0,8%, pResults. Significant differences were obtained for the primary endpoint: DRA 2,7% (n=10), PRA 6,8% (n=26), p=0,008. Distal RA occlusion with patent RA: DRA: 1,3% (n=5), PRA: 0 (n=0), p=0,023. The secondary composite point showed significant differences in the following groups of complications: BARC type I bleeding (DRA: 3,8% (n=14), PRA: 21,7% (n=83), p5 cm on day 1 (DRA: 10% (n=37), PRA: 25,9% (n=98), p5 cm on day 7 (DRA: 12,4% (n=45), PRA: 34,6% (n=132), pConclusion. In the TENDERA study, DRA demonstrated efficacy and safety in interventional coronary procedures compared to PRA in the mid-term follow-up period — significantly lower incidence of RA occlusions and local complications.


  • One year outcomes following of carotid endarterectomy in different age groups: Russian multicenter study

    by Anton Kazantsev, Alexander Korotkikh, Roman Leader, Sergey Artyukhov, Lyudmila Roshkovskaya, Vladimir Unguryan, Maxim Chernyavin, Belov Yury

    Introduction This is a retrospective analysis of the results of carotid endarterectomy (CEA) in different age groups. Methods This cohort, comparative, retrospective, open-label study for the period from 2008 to 2020 included 7248 patients with hemodynamically significant stenoses of the internal carotid artery (ICA), who underwent CEA. According to the classification of the World Health Organization, patients were divided into groups depending on age: up to 44 years—young age (n = 84); 45–60 years—middle age (n = 1635); 61–75—elderly age (n = 4817); over 75 years—senile age (n = 712). Results In terms of the frequency of hospital complications, the group of patients over 75 years of age experienced the largest number of cardiovascular events. One year after surgery, there were no significant differences in the incidence of complications between groups: death (group 1, 1.2%; group 2, 0.5%; group 3, 0.4%; group 4, 1%; p = 0.14), myocardial infarction (group 1, 1.2%; group 2, 0.3%; group 3, 0.14%; group 4, 0.3%; p = 0.12), stroke (group 1, 0%; group 2, 0.3%; group 3, 0.1%; group 4, 0.4%; p = 0.32). Conclusion The largest number of adverse cardiovascular events after CEA are observed among patients over 75 years of age, which is due to the high frequency of multivessel coronary lesions, atrial fibrillation, and the severity of the comorbidities. One year after surgery, there were no significant differences in the incidence of complications between groups.